Stay updated on Avelumab first-line maintenance in Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Avelumab first-line maintenance in Gastric Cancer Clinical Trial page.

Latest updates to the Avelumab first-line maintenance in Gastric Cancer Clinical Trial page
- Check5 days agoChange DetectedA site-wide notice about NIH terminology changes appears above the 403 error page, and the site revision label is updated from v3.7.1 to v3.7.2.SummaryDifference1%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe site footer revision number changes from v3.7.0 to v3.7.1 on the 403 Forbidden page.SummaryDifference0.2%

- Check33 days agoChange DetectedThe page now shows a 403 Forbidden error with a Home button, replacing the previous study record content.SummaryDifference19%

- Check40 days agoChange DetectedThe page now displays Revision: v3.7.0, replacing the previous v3.6.6. This indicates a software deployment or update to the page’s UI/back-end, without altering the study data.SummaryDifference0.0%

- Check54 days agoChange DetectedThe page now shows revision v3.6.6, replacing the previous v3.6.5, indicating a new page revision. This change involves only revision metadata and does not alter study details or visible content.SummaryDifference0.0%

- Check61 days agoChange DetectedThe page now includes a funding attribution for the study, identifying the U.S. NIH Grant/Contract as the funding source.SummaryDifference0.0%

Stay in the know with updates to Avelumab first-line maintenance in Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Avelumab first-line maintenance in Gastric Cancer Clinical Trial page.